ABSTRACT: A series of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles has been identified as a new class of histone deacetylase inhibitors. Compounds 8, 11, 12, 13 , and 14 demonstrated stronger antiproliferative activities than 1 (SAHA) with GI 50 values ranging from 0.36 to 1.21 μM against Hep3B, MDA-MB-231, PC-3, and A549 human cancer cell lines. Lead compound 8 showed remarkable HDAC 1, 2, and 6 isoenzymes inhibitory activities with IC 50 values of 12.3, 4.0, 1.0 nM, respectively, which are comparable to 1. In in vivo efficacy evaluation against lung A549 xenograft model, 8 displayed better antitumor activity than compound 1.
■ INTRODUCTION
Histone acetylation and deacetylation play a crucial role for regulating protein function of eukaryotic cells, which is correlated with two classes of enzymes: histone deacetylases (HDACs) and histone acetyltransferases (HATs). They affected the removal (HDAC) and addition (HAT) of the acetyl group at specific lysine residues. The acetylation status of histone is important in modulating gene expression and cell life, and its dysregulation is involved in the development of several cancers. Histone hyperacetylation leads to transcriptional activation of suppressed genes, some of them being associated with cell cycle arrest, differentiation, or apotosis in tumor cells. Recent studies have shown that acetylation of non-histone proteins is also relevant for tumorigenesis, cancer cell proliferation, and immune functions. Hence, inhibition of HDAC has arisen as an efficient therapeutic strategy to adjust aberrant epigenetic changes associated with cancer. 1−5 In October 2006, small molecule 1 (SAHA, vorinostat) was approved by FDA for the treatment of refractory cutaneous Tcell lymphorma. 6 In November 2009, prodrug 2 (FK-228, romidepsin) also gained approval from FDA for the treatment of cutaneous T-cell lymphoma. 7 Many small molecular agents, for example, 3 (LBH-589), 8 4 (PXD101), 9 and 5 (SB939), 10 are undergoing human clinical trials 11, 12 ( Figure 1) . A close view of these small molecule histone deacetylase inhibitors indicated the hydroxamic acid or the N-hydroxyacrylamide group plays an important role for activity. 13, 14 Our previous studies of antitubulin agents, for example, 3-aroylindoles, 15a 5-aroylindoles, 15b 1-aroylindoles, 15c 3-arylthioindoles, 15d and 1-aryl(1-benzyl)indoles, 15e−g showed substantial anticancer activity. The literature 16 reported that the 2-aroyl-5-(Nhydroxyacrylamide)indoles exhibited potent histone deacetylation inhibition. On the basis of these observations, we attempted to explore the structure−activity relationships between the indole moiety and the N-hydroxyacrylamide group. Using the 1-arylsulfonylindole as a base coupled with the N-hydroxyacrylamide group at the C-3, -4, -5, -6, or -7 position of indole ring provided the regioisomers of indolyl-Nhydroxyacrylamides and allowed evaluation of bioactivity ( Figure 2 ). Herein we describe the discovery of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as a new class of histone deacetylase inhibitors showing antitumor activity in vivo.
■ RESULTS AND DISCUSSION
Chemistry. The synthesis of 3-(N-hydroxyacrylamide)-indole (6) is depicted in Scheme 1. Compound 22 was reacted with the O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (NH 2 OTHP) in the presence of benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PYBOP) and Et 3 N to prepare the tetrahydropyran-protected compound 23, which was further subjected to the N1-benzenesulfonylation of indole in the presence of KOH and tetrabutylammonium hydrogen sulfate (TBAHS) at room temperature and then trifluoroacetic acid (TFA) mediated deprotection to afford the desired 6. The general method for the syntheses of 4-, 5-, 6-, and 7-(Nhydroxyacrylamide)indoles 7−10 and 1-arylsulfonyl-5-(Nhydroxyacrylamide)indoles 11−14 are shown in the Scheme 2. The preparation of compounds 7−10 involved a five-step reaction sequence, with an overall yield of 34−52%. The various commercially available indolecarboxyaldehydes (24− 27) with benzenesulfonyl chloride yielded the related 1-benzenesulfonylindoles (28−31). These indoles-1-sulfonamides were subject to the Wittig reaction with methyl (triphenylphosphorylidene)acetate followed by LiOH hydrolysis and PYBOP-mediated amide formation, and the reaction sequence was completed by TFA-mediated deprotection to afford the desired 1-benzenesulfonyl(N-hydroxyacrylamide)-indoles 7−10. The 1-substituted phenylsulfonyl compounds 11−14 were synthesized in 41−61% yields from compound 25 by reacting with the corresponding arylsulfonyl chloride in the presence of KOH and tetrabutylammonium hydrogen sulfate (TBAHS) at room temperature. Compound 15, with a hydroxyamide group at the C-5 position of the indole ring, was synthesized in 40% yield by treatment of indole 5-methylcarboxylate (44) with 1-phenylsulfonylation, LiOHmediated hydroxylation, NH 2 OTHP/PYBOP coupling reaction, and TFA deprotection (Scheme 3). Similar to the preparation of compound 8, compounds 16, 17, and 18, with a benzoyl, benzyl, and phenyl group at the N1-position, were obtained in 5−63% yield through a five-step synthesis as shown in the Scheme 4. The 1-benzoylation and benzylation of indole-5-carboxyaldehyde (25) was achieved by using KO-t-Bu as base in the presence of KI and DMF at room temperature. The 1-arylation of the indole ring was achieved in 28% yield by the treatment of 25 and 4-iodobenzene with CuO/K 2 CO 3 in DMF. As shown in the Scheme 5, the treatment of compound 8 with KOH and Pd/C afforded the desired compounds 19 and 20, respectively. The synthesis of 3-(benzenesulfonyl)-5-(Nhydroxyacrylamide)indole (21) is described in Scheme 6. Starting from the indole-5-carboxyaldehyde (25), the 3-arylsulfonyl-5-(methylacrylate)indole 54 was obtained by methyl(triphenylphosphoranylidene)acetate-mediated Wittig reaction, diphenyl disulfide mediated electrophilic substitution, and mCPBA oxidation. The conversion of methyl acrylate (54) to N-hydroxyacrylamide (21) was accomplished by a reaction sequence, including the LiOH hydrolysis, NH 2 OTHP/PYBOP coupling reaction, and TFA deprotection.
Biological Evaluation. (A) HeLa Nuclear HDAC Enzyme Inhibition. First, we evaluated the position effect of the Nhydroxyacrylamide group in the 1-benzenesulfonylindole system as shown in Table 1 . The regioisomers 3-, 4-, 5-, 6-, and 7-(N-hydroxyacrylamide)-1-benzenesulfonylindoles (6, 7, 8, 9 , and 10, respectively) were evaluated for the inhibition of HeLa nuclear HDAC activity (which consists of pan-HDAC isoenzymes). The N-hydroxyacrylamide moiety located at the C-5 position on the indole ring resulted in the best activity among the five regioisomers with 1-benzenesulfonyl-5-(Nhydroxyacrylamide)indole (8) showing IC 50 values of 29.5 nM on HeLa HDAC enzyme inhibition, which was more potent than 1 (IC 50 = 96.4 nM). Shifting of the N-hydroxyacrylamide group to the C-4 (7) and C-6 (9) positions resulted in a decrease in enzyme activity to the 100 nM level, while moving to the C-3 and C-7 positions, as in compounds 6 and 10, respectively, resulted in the loss of HDAC enzyme activity. Second, we expanded the panel construction using indole 8 as motif. Further investigation of substitution effects on the N1-benzenesulfonyl group of compound 8 revealed that 11 with an additional methoxy group at the C-4′ position, 12 with the dimethoxy substitution at the C-3′ and C-4′ positions, 13 with a fluoro group at the C-4′ position, and 14 with a nitro group at C-4′ position all exhibited substantial activities with IC 50 values of 6.8, 9.7, 16.8, and 12.6 nM, respectively. In an effort to further understand the role of N-hydroxyacrylamide substituent at the C-5 position of indole ring, compound 15 (with two carbons shorter than 8) and compound 20 (with a saturated double from 8) were prepared. They exhibited a decrease in potency, thus emphasizing the importance of N-hydroxyacrylamide at the C-5 position of indole in inhibiting HDAC enzyme activity. In order to understand the role of 1-sulfonyl functionality in 8, 1-benzoyl, 1-benzyl, and 1-phenyl substituted compounds 16, 17, and 18, respectively, were prepared. Compound 17, with a benzyl group, retained HDAC enzyme activity comparable to that of 8, but benzoyl (16) or phenyl (18) substitution resulted in a decrease in activity, thus revealing that the 1-benzenesulfonyl and 1-benzyl group in the indol-5-yl-N-hydroxyacrylamide series were preferable. The removal of 1-benzenesulfonyl group in 8, for example, compound 19, resulted in a dramatic loss of activity, indicating the 1-arylsulfonyl group played a vital role for activity in this series. Changing the position of arylsulfonyl group from N-1 to C-3 on the indole ring, for example, compound 21, caused a reduced potency.
(B) In Vitro Cell Growth Inhibitory Activity. Other compounds with the N-hydroxyacrylamide group at the C-3, C-4, C-6, C-7 position of 1-(arylsulfonyl)indoles (6, 7, 9, 10), benzoyl, phenyl, and no substitution at the N1 of 5-(Nhydroxyacrylamide)indoles (16, 18, 19) , and modifications to the C-5 position from 8 (15, 20) had significantly less antiproliferative activities.
(C) HDAC Isoform Inhibition. The 1-arylsulfonyl-5-(Nhydroxyacrylamide)indoles 8, 11, 12, 13, 14, and 17 were tested for HDAC isoform enzyme-inhibitory activity (HDACs 1, 2, and 6) using compound 1 as a reference (Table 2 ). Compound 8 with 1-benzenesulfonyl group had low nanomolar IC 50 values against HDACs 2 and 6 with IC 50 values of 1 and 4 nM, respectively. Compound 11 with 4′-methoxyphenylsulfonyl group displayed high activity on HDAC 6 (IC 50 = 3.3 nM) and 40-to 100-fold selectivity for HDACs 1 and 2. However, compound 12 with a dimethoxy group at both C-3′ and C-4′ positions exhibited selective and potent inhibitory activity for HDAC 2, with IC 50 of 2.3 nM, among HDACs 1, 2, and 6. The results indicated that the position of introduced methoxy group in the 1-arylsulfonyl group of 5-(N-hydroxyacrylamide)indoles seems to affect selectivity between HDAC isoforms. Compounds 13 and 14, with a fluoro and nitro substitution at the 4′-position of the arylsulfonyl moiety, respectively, exhibited diminished activities against HDACs 1, 2, and 6 compared with parent compound 8.
(D) Up-Regulation Effect of Histone and α-Tubulin. In an effort to further validate the target in the 1-(arylsulfonyl)-5-(N- hydroxyacrylamide)indole series, compound 8 was evaluated for the expression of histone and α-tubulin acetylation in PC-3 prostate cancer cell lines and A549 non-small-cell lung cancer cells, which were important biomarkers associated with intracellular HDAC inhibition. Western blot analysis of the cell lysates revealed that compound 8, like compound 1, was a pan-HDAC inhibitor on the basis of its ability to up-regulate H3 and tubulin acetylation in dose-dependent manner ( Figure  3) .
(E) CYP Inhibition and Pharmacokinetic Study. (E.1) Effect of 8 on Cytochrome P450 Isozymes. Compound 8 was tested for its inhibition of CYP1A2, 2C19, 2C8, 2C9, 2D6, 2E1, and 3A4 at 10 μM ( Table 3 ). The CYP inhibition of 8 was greatest for CYP2C19 and CYP2C8 with 78% at 10 μM. Both CYP3A4 and CYP1A2 were also affected to a lesser extent, 65% and 51% at 10 μM, respectively. Compound 8 has a solubility of <1 μg/mL in water and 939 μg/mL in EtOH.
(E.2) In Vivo Rat PK Profiling of 8. The PK parameters of 8 in male Sprague−Dawley rats, following single dose intravenous (iv) and oral dosing, are shown in Table 4 . Following iv administration, 8 showed a mean T 1/2 of 2.6 h. After a single oral dose, compound 8 showed rapid absorption with T max = 1.7 h, T 1/2 = 5.5 h, and bioavailability F = 10%.
(F) In Vivo Efficacy in Human Xenograft. Compound 8 and reference compound 1 were evaluated for in vivo efficacy of tumor xenograft in nude mice bearing human A549 cancer cell line expressed by tumor growth delay (TGD; Figure 4A , Table  5 ) and tumor growth inhibition (TGI; Figure 4B ). Once tumor was palpable with a size of ∼65 mm 3 , mice were randomized into vehicle control and treatment groups of seven animals each. Control mice received vehicle (0.5% carboxymethyl cellulose). Compounds 8 and 1 were suspended in the 0.5% carboxymethyl cellulose. All tumors in mice grew to the 1000 mm 3 end point volume. The median TTE (time to end point) for control mice was 27.0 days. Compound 1, at 200 mg/kg po daily to end, produced a median TTE of 30.0 days, corresponding to a 3.0 day T − C and a TGD (tumor growth delay) of 11%. On the basis of the log rank analysis, compound 1 did not produce significant antitumor activity (P = 0.3925). However, compound 8, at 200 and 100 mg/kg po daily to end, produced a median TTE of 39.8 and 36.2 days, corresponding to a 12.8 and 9.2 day T − C and a TGD of 47% and 34%, respectively. On the basis of the log rank analysis, compound 8 exhibits significant antitumor activity at 200 mg/kg (P = 0.0274) but not at 100 mg/kg (P = 0.1668). Results indicated that there was a dose-dependent delay of tumor growth in 8. 3 nM, respectively, comparable to compound 1. Structure−activity relationship information revealed that the N-hydroxyacrylamide group located at the C-5 position of indole ring displayed the best activity compared to other positions such as the C-3, -4, -6, and -7 positions. The 1-arylsulfonyl substitution pattern contributed to a significant extent for maximal activity, for example, compounds 8, 11, 12, 13, and 14 showed better activity compared to benzoyl, benzyl, or phenyl group substituted compounds. In an in vivo efficacy evaluation against human xenograft model in nude mice bearing lung A549 cancer cell line, compound 8 demonstrated greater antitumor activity than compound 1. There was a 47% tumor growth delay (32% tumor growth inhibition) on treatment with 8 daily at 200 mg/ kg po. In summary, compound 8 has potential in further investigations as anticancer agents.
■ EXPERIMENTAL SECTION
Chemistry. Nuclear magnetic resonance ( 1 H NMR) spectra were obtained with a Bruker DRX-500 spectrometer (operating at 500 MHz), with chemical shift in parts per million (ppm, δ) downfield from TMS as an internal standard. Mass spectrometry (MS) data were measured on a JEOL JMS-700 mass spectrometer (HRMS-EI and MS-EI), Finnigan TSQ 700 mass spectrometer (MS-EI), and micrOTOF orthogonal ESI-TOF mass spectrometer (HRMS-ESI). Purity of the final compounds was determined using a Hitachi 2000 series HPLC system using C-18 column (Agilent ZORBAX Eclipse XDB-C18 5 μm, 4.6 mm × 150 mm) with the solvent system (elution conditions: mobile phase A consisting of acetonitrile; mobile phase B consisting of water containing 0.1% formic acid +10 mmol NH 4 OAc) and was found to be ≥95%. Flash column chromatography was done using silica gel (Merck Kieselgel 60, no. 9385, 230−400 mesh ASTM). All reactions were carried out under an atmosphere of dry nitrogen.
Syntheses of 1-Phenylsulfonyl-(N-hydroxyacrylamide)-indoles 6−10. 3-(1H-Indol-3-yl)-N-(tetrahydropyran-2-yloxy)-acrylamide (23). To a solution of trans-3-indoleacrylic acid (22, 0.50 g, 2.67 mmol), PYBOP (1.47 g, 2.83 mmol), and triethylamine (0.74 mL, 6.41 mmol) in THF (25 mL) was added NH 2 OTHP (0.38 g, 3.21 mmol), and the mixture was stirred at room temperature. After being stirred for 2 h, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc and quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((EtOAc/n-hexane = 1.5:1)/1% NH 3(aq) ) to give compound 23. Yield 68%. 
. After a suspension of 23 (0.52 g, 1.82 mmol), TBAHS (0.09 g, 0.27 mmol), and KOH (0.20 g, 3.63 mmol) in CH 2 Cl 2 (15 mL) was stirred for 20 min, benzenesulfonyl chloride (0.35 mL, 2.72 mmol) was added. The mixture was stirred at room temperature for 16 h. The reaction was quenched with water, and extraction was with CH 2 Cl 2 (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 , concentrated under reduced pressure, and dried with vacuum to give a yellow residue without purification, which was dissolved in methanol (50 mL) and treated with TFA (2.2 mL, 29.8 mmol). The mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure to give a yellow residue, which was recrystallized by CH 3 .89 mmol) in CH 2 Cl 2 (15 mL) was stirred for 20 min, benzenesulfonyl chloride (0.66 mL, 5.17 mmol) was added, and the mixture was stirred at room temperature overnight. The reaction was quenched with water, and extraction was with CH 2 Cl 2 (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give a yellow residue, which was purified by silica gel chromatography (EtOAc/n-hexane = 1:3) to afford compound 28. Yield 85%. 3-(1-Benzenesulfonyl-1H-indol-4-yl)acrylic Acid (32). To a solution of 28 (0.2 g, 0.7 mmol) in CH 2 Cl 2 (10 mL) was added methyl (triphenylphosphoranylidene)acetate (0.28 g, 0.84 mmol), and the mixture was stirred at room temperature. After being stirred for 16 h, the reaction mixture was quenched with water and extracted with CH 2 Cl 2 (25 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give a yellow residue, which was purified by silica gel chromatography (EtOAc/n-hexane = 1:2) to give the acrylic acid methyl ester compound. Yield 88%. 1 To a solution of ester compound (0.2 g, 0.58 mmol) in dioxane (10 mL), 1 M LiOH (aq) (1.2 mL) was added. The mixture was stirred at 40°C
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. After being stirred for 12 h, the mixture was concentrated under reduced pressure. The residue was dissolved in water. Concentrated HCl was added to obtain acidic pH to produce a precipitate, which was recrystallized by CH 3 
. To a solution of 32 (0.2 g, 0.61 mmol), PYBOP (0.34 g, 0.65 mmol), and triethylamine (0.2 mL, 1.47 mmol) in DMF (1.5 mL) was added NH 2 OTHP (0.09 g, 0.73 mmol), and the mixture was stirred at room temperature. After the mixture was stirred for 2 h, the reaction was quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((CH 2 Cl 2 /CH 3 OH = 30:1)/1% NH 3(aq) ) to give a white solid, which was treated with TFA (1.9 mL, 25.58 mmol) in the presence of CH 3 OH (35 mL). The mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure to give a white residue, which was recrystallized by CH 3 OH to afford the desired 7. Yield 72%; mp 100−102°C. 1-Benzenesulfonyl-1H-indole-5-carbaldehyde (29). After a suspension of 1H-indole-5-carbaldehyde (25, 1.00 g, 6.89 mmol), TBAHS (0.35 g, 1.03 mmol), and KOH (0.77 g, 13.78 mmol) in CH 2 Cl 2 (30 mL) was stirred for 20 min, benzenesulfonyl chloride (1.32 mL, 10.33 mmol) was added. The mixture was stirred at room temperature for 16 h. The reaction was quenched with water, and extraction was with CH 2 Cl 2 (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give a yellow residue, which was purified by silica gel chromatography (EtOAc/n-hexane = 1:2) to afford compound 29. Yield 91%. 1 3-(1-Benzenesulfonyl-1H-indol-5-yl)acrylic Acid (33). To a solution of 29 (1.79 g, 6.27 mmol) in CH 2 Cl 2 (25 mL), methyl (triphenylphosphoranylidene)acetate (2.52 g, 7.53 mmol) was added, and the mixture was stirred at room temperature. After being stirred overnight, the reaction mixture was quenched with water and extracted with CH 2 Cl 2 (25 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give the methyl ester compound as a yellow residue for the next reaction.
To a solution of methyl ester residue in dioxane (20 mL), 1 M LiOH aqueous solution (11.7 mL) was added. The mixture was stirred at 40°C. After being stirred for 16 h, the mixture was concentrated under reduced pressure. The residue was dissolved in water, and concentrated HCl was added to obtain acidic pH to produce the precipitate, which was recrystallized by CH 3 OH and dried by vacuum to afford compound 33. Yield 80% (two steps). 1 3-(1-Benzenesulfonyl-1H-indol-5-yl)-N-hydroxyacrylamide (8) . To a solution of 33 (1.00 g, 3.05 mmol), PYBOP (1.69 g, 3.24 mmol), and triethylamine (1.02 mL, 7.33 mmol) in DMF (1.5 mL) was added NH 2 OTHP (0.43 g, 3.67 mmol), and the mixture was stirred at room temperature. After the mixture was stirred for 3 h, the reaction was quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((CH 2 Cl 2 /CH 3 OH = 30:1)/1% NH 3(aq) ) to give a white solid, which was treated with TFA (6.90 mL, 92.90 mmol) in the presence of CH 3 OH (140 mL) and stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure to give a white residue, which was recrystallized by EtOAc/EtOH to afford the desired 8. 3-(1-(Phenylsulfonyl)-1H-indol-6-yl)acrylic Acid (34). To a solution of 30 (1.0 g, 3.5 mmol) in CH 2 Cl 2 (20 mL) was added methyl (triphenylphosphoranylidene)acetate (1.4 g, 4.2 mmol), and the mixture was stirred at room temperature. After being stirred for 16 h, the reaction mixture was quenched with water and extracted with CH 2 Cl 2 (25 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give the methyl ester compound as a yellow residue for the next reaction.
To a solution of crude methyl ester in dioxane (20 mL) was added 1 M LiOH (aq) (7 mL), and the mixture was stirred at 40°C. After being stirred for 12 h, the mixture was concentrated under reduced pressure. The residue was dissolved in water, and concentrated HCl was added to give acidic pH to produce the precipitate, which was recrystallized by CH 3 OH and dried by vacuum to afford compound 34. Yield 79% (two steps). 3-(1-Benzenesulfonyl-1H-indol-6-yl)-N-hydroxyacrylamide (9). To a solution of 34 (0.3 g, 0.92 mmol), PYBOP (0.51 g, 0.97 mmol), and triethylamine (0.31 mL, 2.2 mmol) in DMF (2 mL) was added NH 2 OTHP (0.13 g, 1.10 mmol), and the mixture was stirred at room temperature. After the mixture was stirred for 3 h, the reaction was quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((CH 2 Cl 2 /CH 3 OH = 30:1)/1% NH 3(aq) ) to give a white solid, which was treated with TFA (2.1 mL, 28.27 mmol) in the presence of CH 3 OH (42 mL). The mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure to give a red residue, which was recrystallized by CH 3 OH to afford the desired 9. Yield 64%; mp 166−168°C. (1.46 g, 4.38 mmol) , and the mixture was stirred at room temperature. After being stirred overnight, the reaction mixture was quenched with water and extracted with CH 2 Cl 2 (25 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give the methyl ester as a yellow residue for the next reaction.
To a solution of crude methyl ester in dioxane (25 mL) was added 1 M LiOH (aq) (7.3 mL), and the mixture was stirred at 40°C. After being stirred for 12 h, the mixture was concentrated under reduced pressure. The residue was dissolved in water, and concentrated HCl was added to obtain acidic pH to produce the precipitate, which was recrystallized and dried by vacuum to afford compound 35. Yield 85% (two steps). , and triethylamine (0.2 mL, 1.47 mmol) in DMF (1.5 mL) was added NH 2 OTHP (0.09 g, 0.73 mmol), and the mixture was stirred at room temperature. After the mixture was stirred for 3 h, the reaction was quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((CH 2 Cl 2 /CH 3 OH = 30:1)/1% NH 3(aq) ) to give a white solid, which was treated with TFA (1.4 mL, 18.85 mmol) in the presence of CH 3 OH (28 mL). The mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure to give a white residue, which was recrystallized by CH 3 OH to afford the desired compound 10. Yield 62%; mp 177−178°C 03 mmol), and KOH (0.77 g, 13.78 mmol) in CH 2 Cl 2 (20 mL) was stirred for 20 min, 4-methoxybenzenesulfonyl chloride (2.14 g, 10.33 mmol) was added, and the mixture was stirred at room temperature overnight. The reaction was quenched with water, and extraction was with CH 2 Cl 2 (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give a yellow residue, which was purified by silica gel chromatography (EtOAc/nhexane = 1:2) to afford compound 36. Yield 88%. 1 
3-[1-(4-Methoxybenzenesulfonyl)-1H-indol-5-yl]acrylic Acid (40).
To a solution of 36 (1.91 g, 6.06 mmol) in CH 2 Cl 2 (20 mL) was added methyl (triphenylphosphoranylidene)acetate (2.43 g, 7.27 mmol), and the mixture was stirred at room temperature. After being stirred overnight, the reaction mixture was quenched with water and extracted with CH 2 Cl 2 (25 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give the methyl ester as a yellow residue for the next reaction.
To a solution of crude methyl ester in dioxane (40 mL) was added 1 M LiOH (aq) (12.2 mL), and the mixture was stirred at 40°C. After being stirred for 12 h, the mixture was concentrated under reduced pressure. The residue was dissolved in water, and concentrated HCl was added to obtain acidic pH to produce the precipitate, which was recrystallized and dried by vacuum to afford compound 40. Yield 89% (two steps). 1 (11) . To a solution of 40 (0.2 g, 0.56 mmol), PYBOP (0.32 g, 0.62 mmol), and triethylamine (0.19 mL, 1.34 mmol) in DMF (2 mL) was added NH 2 OTHP (0.08 g, 0.67 mmol), and the mixture was stirred at room temperature. After the mixture was stirred for 3 h, the reaction was quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((CH 2 Cl 2 /CH 3 OH = 30:1)/1% NH 3(aq) ) to give a white solid, which was treated with TFA (1.3 mL, 17.34 mmol) in the presence of CH 3 OH (27 mL). The mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure to give a white residue, which was recrystallized by CH 3 OH to afford compound 11. 76 mmol), TBAHS (0.14 g, 0.41 mmol), and KOH (0.31 g, 5.51 mmol) in CH 2 Cl 2 (15 mL) was stirred for 20 min, 3,4-dimethoxybenzenesulfonyl chloride (0.98 g, 4.13 mmol) was added, and the mixture was stirred at room temperature for 16 h. The reaction was quenched with water, and extraction was with CH 2 Cl 2 (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give a yellow residue 37, which was dissolved in CH 2 Cl 2 (15 mL) and then treated with methyl (triphenylphosphoranylidene)acetate (1.11 g, 3.31 mmol) at room temperature. After being stirred overnight, the reaction mixture was quenched with water and extracted with CH 2 Cl 2 (25 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give the methyl ester compound as a yellow residue for the next reaction.
To a solution of crude methyl ester in dioxane (25 mL) was added 1 M LiOH (aq) (5.5 mL), and the mixture was stirred at 40°C. After the mixture was stirred for 12 h, the reaction was concentrated under reduced pressure. The residue was dissolved in water, and concentrated HCl was added to obtain acidic pH to produce the precipitate, which was recrystallized and dried by vacuum to afford compound 41. Yield 78% (three steps). (12) . To a solution of 41 (0.2 g, 0.52 mmol), PYBOP (0.3 g, 0.57 mmol), and triethylamine (0.17 mL, 1.25 mmol) in DMF (2 mL) was added NH 2 OTHP (0.07 g, 0.62 mmol), and the mixture was stirred at room temperature. After the mixture was stirred for 2 h, the reaction was quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((CH 2 Cl 2 /CH 3 OH = 30:1)/1% NH 3(aq) ) to give a white solid, which was treated with TFA (1.2 mL, 16.1 mmol) in the presence of CH 3 OH (25 mL). The mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure to give a yellow residue, which was recrystallized by CH 3 OH to afford the desired compound 12. Yield 53%; mp 146−148°C. 1 To a solution of crude methyl ester in dioxane (30 mL) was added 1 M LiOH (aq) (6.6 mL) was added, and the mixture was stirred at 40°C. After being stirred for 12 h, the mixture was concentrated under reduced pressure. The residue was dissolved in water, and concentrated HCl was added to obtain acidic pH to produce the precipitate, which was recrystallized and dried by vacuum to afford compound 42. Yield 90% (two steps). 1 64 mmol), and triethylamine (0.19 mL, 1.39 mmol) in DMF (1.5 mL) was added NH 2 OTHP (0.08 g, 0.70 mmol), and the mixture was stirred at room temperature. After the mixture was stirred for 3 h, the reaction was quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((CH 2 Cl 2 /CH 3 OH = 30:1)/1% NH 3(aq) ) to give a white solid, which was treated with TFA (1.3 mL, 18 mmol) in the presence of CH 3 OH (28 mL). The mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure to give a white residue, which was recrystallized by CH 3 OH to afford the desired compound 13. Yield 76%; mp 138−140°C. (0.61 g, 1.82 mmol) , and the mixture was stirred at room temperature. After being stirred overnight, the reaction mixture was quenched with water and extracted with CH 2 Cl 2 (25 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give a methyl ester yellow residue for the next reaction.
To a solution of crude methyl ester in dioxane (15 mL) was added 1 M LiOH (aq) (3.1 mL), and the mixture was stirred at 40°C. After being stirred for 12 h, the mixture was concentrated under reduced pressure. The residue was dissolved in water, and concentrated HCl was added to obtain acidic pH to produce the precipitate, which was recrystallized and dried by vacuum to afford compound 43. Yield 82% (two steps). (14) . To a solution of 43 (0.2 g, 0.54 mmol), PYBOP (0.31 g, 0.59 mmol), and triethylamine (0.18 mL, 1.3 mmol) in DMF (1.5 mL) was added NH 2 OTHP (0.08 g, 0.65 mmol), and the mixture was stirred at room temperature. After the mixture was stirred for 3 h, the reaction was quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((CH 2 Cl 2 /CH 3 OH = 30:1)/1% NH 3(aq) ) to give a white solid, which was treated with TFA (1.2 mL, 16.7 mmol) in the presence of CH 3 OH (27 mL). The mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure to give a white residue, which was recrystallized by CH 3 OH to afford the desired compound 14. Yield 65%; mp 154−156°C. 1 19 g, 3 .42 mmol) in CH 2 Cl 2 (15 mL) was stirred for 20 min, benzenesulfonyl chloride (0.32 mL, 2.57 mmol) was added, and the mixture was stirred at room temperature for 16 h. The reaction was quenched with water, and extraction was with CH 2 Cl 2 (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give a yellow residue, which was purified by silica gel chromatography (EtOAc/n-hexane = 1:4) to afford the 1-phenylsulfonyl indole compound as a white solid. Yield 89%. 1 To a solution of 1-phenylsulfonylindole (0.52 g, 1.65 mmol) in dioxane (15 mL) was added 1 M LiOH aqueous solution (3.8 mL), and the mixture was stirred at 40°C. After being stirred overnight, the mixture was concentrated under reduced pressure. The residue was dissolved in water, and concentrated HCl was added to obtain acidic pH to produce the precipitate, which was dried by vacuum to afford compound 45. Yield 85%. 1 1-Benzenesulfonyl-1H-indole-5-carboxylic Acid Hydroxyamide (15). To a solution of 45 (0.18 g, 0.60 mmol), PYBOP (0.33 g, 0.63 mmol), and triethylamine (0.20 mL, 1.43 mmol) in DMF (1.5 mL) was added NH 2 OTHP (0.08 g, 0.72 mmol), and the mixture was stirred at room temperature. After the mixture was stirred for 2 h, the reaction was quenched with water, followed by extraction with EtOAc (15 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((CH 2 Cl 2 /CH 3 OH = 30:1)/1% NH 3(aq) ) to give a white solid, which was treated with TFA (1.70 mL, 22.89 mmol) in the presence of CH 3 OH (31 mL). The mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure to give a white residue, which was purified by silica gel chromatography (CH 2 Cl 2 /CH 3 OH = 30:1) to afford the desired 15 as a colorless oil. Yield 53%. , and potassium tert-butoxide (0.64 g, 5.71 mmol) in DMF (2 mL) was stirred for 15 min, benzoyl bromide (0.50 mL, 4.28 mmol) was added, and the mixture was stirred at room temperature for 16 h. The reaction was quenched with water, and extraction was with CH 2 Cl 2 (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 , concentrated under reduced pressure, and dried with vacuum to give a yellow residue, which was purified by silica gel chromatography (EtOAc/n-hexane = 1:2) to afford compound 46. Yield 87%. 3-(1-Benzoyl-1H-indol-5-yl)acrylic Acid (49). To a solution of 46 (0.62 g, 2.03 mmol) in CH 2 Cl 2 (15 mL) was added methyl (triphenylphosphoranylidene)acetate (0.81 g, 2.44 mmol), and the mixture was stirred at room temperature. After being stirred for 16 h, the reaction mixture was quenched with water and extracted with CH 2 Cl 2 (25 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give a methyl ester yellow residue for the next reaction.
To a solution of crude methyl ester in dioxane (10 mL) was added 1 M LiOH (aq) (4.1 mL), and the mixture was stirred at 40°C. After being stirred for 12 h, the mixture was concentrated under reduced pressure. The residue was dissolved in water, and concentrated HCl was added to obtain acidic pH to produce the precipitate, which was recrystallized and dried by vacuum to afford compound 49. Yield 82% (two steps). 3-(1-Benzoyl-1H-indol-5-yl)-N-hydroxyacrylamide (16) . To a solution of 49 (0.1 g, 0.34 mmol), PYBOP (0.05 g, 0.41 mmol), and triethylamine (0.12 mL, 0.82 mmol) in DMF (1.5 mL) was added NH 2 OTHP (0.05 g, 0.41 mmol), and the mixture was stirred at room temperature. After the mixture was stirred for 3 h, the reaction was quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((CH 2 Cl 2 /CH 3 OH = 30:1)/1% NH 3(aq) ) to give a white solid, which was treated with TFA (0.78 mL, 10.5 mmol) in the presence of CH 3 OH (16 mL). The mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure to give a white residue, which was recrystallized by CH 3 1-Benzyl-1H-indole-5-carbaldehyde (47). After a suspension of 1H-indole-5-carbaldehyde (25, 0.5 g, 3.44 mmol), KI (0.29 g, 1.72 mmol), and potassium tert-butoxide (0.77 g, 6.89 mmol) in DMF (3 mL) was stirred for 15 min, benzyl chloride (0.8 mL, 6.89 mmol) was added. The mixture was stirred at room temperature for 16 h. The reaction was quenched with water, and extraction was with CH 2 Cl 2 (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 , concentrated under reduced pressure, and dried with vacuum to give a yellow residue, which was purified by silica gel chromatography (EtOAc/n-hexane = 1:3) to afford compound 47. Yield 85%. 3-(1-Benzyl-1H-indol-5-yl)acrylic Acid (50). To a solution of 47 (0.3 g, 1.28 mmol) in CH 2 Cl 2 (10 mL) was added methyl (triphenylphosphoranylidene)acetate (0.51 g, 1.53 mmol), and the mixture was stirred at room temperature. After being stirred for 16 h, the reaction mixture was quenched with water and extracted with CH 2 Cl 2 (25 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 , concentrated under reduced pressure, and dried with vacuum to give a brown residue, which was purified by silica gel chromatography (EtOAc/n-hexane = 1:3) to afford the methyl ester compound as an orange solid. Yield 85%. To a solution of methyl ester (0.32 g, 1.10 mmol) in dioxane (10 mL) was added 1 M LiOH (aq) (2.2 mL), and the mixture was stirred at 40°C. After being stirred overnight, the mixture was concentrated under reduced pressure. The residue was dissolved in water, and concentrated HCl was added to obtain acidic pH to produce the precipitate, which was dried by vacuum to afford compound 50. Yield 91%. 1 3-(1-Benzyl-1H-indol-5-yl)-N-hydroxyacrylamide (17) . To a solution of 50 (0.1 g, 0.4 mmol), PYBOP (0.23 g, 0.44 mmol), and triethylamine (0.13 mL, 0.96 mmol) in DMF (1 mL) was added NH 2 OTHP (0.06 g, 0.48 mmol), and the mixture was stirred at room temperature. After the mixture was stirred for 1 h, the reaction was quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((CH 2 Cl 2 /CH 3 OH = 30:1)/1% NH 3(aq) ) to give a white solid, which was treated with TFA (0.92 mL, 12.4 mmol) in the presence of CH 3 OH (19 mL). The mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure to give a white residue, which was recrystallized by CH 3 OH to afford the desired 17. Yield 81%; mp 133−135°C. was quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure to give a yellow residue, which was purified by silica gel chromatography (EtOAc/n-hexane = 1:4) to afford compound 48. Yield 28%. 1 3-(1-Phenyl-1H-indol-5-yl)acrylic Acid (51). To a solution of 48 (0.29 g, 1.31 mmol) in CH 2 Cl 2 (10 mL) was added methyl (triphenylphosphoranylidene)acetate (0.52 g, 1.57 mmol), and the mixture was stirred at room temperature. After being stirred for 16 h, the reaction mixture was quenched with water and extracted with CH 2 Cl 2 (25 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 , concentrated under reduced pressure, and dried with vacuum to give a brown residue, which was purified by silica gel chromatography (EtOAc/n-hexane = 1:5) to afford the methyl ester compound as a yellow liquid. Yield 92%. To a solution of the methyl ester compound (0.31 g, 1.12 mmol) in dioxane (10 mL) was added 1 M LiOH (aq) (2.3 mL), and the mixture was stirred at 40°C. After being stirred for 12 h, the mixture was concentrated under reduced pressure. The residue was dissolved in water, and concentrated HCl was added to obtain acidic pH to produce the precipitate, which was dried by vacuum to afford compound 51. Yield 48%. N-Hydroxy-3-(1-phenyl-1H-indol-5-yl)acrylamide (18) . To a solution of 51 (0.2 g, 0.76 mmol), PYBOP (0.43 g, 0.84 mmol), and triethylamine (0.25 mL, 1.82 mmol) in DMF (1.5 mL) was added NH 2 OTHP (0.11 g, 0.91 mmol), and the mixture was stirred at room temperature. After the mixture was stirred for 2 h, the reaction was quenched with water, followed by extraction with EtOAc (20 mL × 3). The combined organic layer was dried over anhydrous MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography ((CH 2 Cl 2 /CH 3 OH = 30:1)/1% NH 3(aq) ) to give a white solid, which was treated with TFA (1.8 mL, 24.2 mmol) in the presence of CH 3 OH (36 mL). The mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure to give a white residue, which was recrystallized by CH 3 Synthesis of 5-(N-Hydroxyacrylamide)indole 19. N-Hydroxy-3-(1H-indol-5-yl)acrylamide (19) . 8 (0.20 g, 0.58 mmol) was dissolved in MeOH (8 mL), and to the mixture was added 1 M KOH (aq) (1.16 mL, 1.16 mmol). The mixture was stirred and refluxed for 1 h. The reaction was quenched by water, and extraction was with ethyl acetate (30 mL × 3). The organic layer was collected and dried over anhydrous MgSO 4 and concentrated in vacuo to yield a colorless product. The residue was purified by flash column chromatography over silica gel (EtOAc/n-hexane = 2:1) to afford 19. Yield 51%; mp 162−164°C Biology. HeLa Nuclear Extract HDAC Activity Assay. 17 The HeLa nuclear extract HDAC activity was measured by using the HDAC fluorescent activity assay kit (BioVision, CA) according to the manufacturer's instructions. Briefly, the HDAC fluorometric substrate and assay buffer were added to HeLa nuclear extracts in a 96-well format and incubated at 37°C for 30 min. The reaction was stopped by adding lysine developer, and the mixture was incubated for another 30 min at 37°C. Additional negative controls included incubation without the nuclear extract, without the substrate, or without both. TSA at 1 μM served as the positive control. A fluorescence plate reader with excitation at 355 nm and emission at 460 nm was used to quantify HDAC activity.
HDAC Biochemical Assays. 18 The HDAC in vitro activities of recombinant human HDACs 1, 2, 6, and 8 (BPS Biosciences) were detected by fluorigenic release of 7-amino-4-methylcoumarin from substrate upon deacetylase enzymatic activity.
Tumor Cell Culture. All human cancer cells were maintained in RPMI 1640 medium containing 100 units/mL penicillin G sodium, 100 μg/mL streptomycin sulfate, 0.25 μg/mL amphotericin B, and 25 μg/mL gentamicin. The medium was supplemented with 10% fetal bovine serum and 2 mM glutamine. The cells were cultured in tissue culture flasks in a humidified incubator at 37°C, in an atmosphere of 5% CO 2 and 95% air.
Sulforhodamine B Assays. 19 Human cancer A549 (non-smallcell lung cancer), MDA-MB-231 (estrogen-independent breast cacner), Hep 3B (hepatoma), and PC-3 (prostate) cells were seeded in 96-well plates in medium with 5% FBS. After 24 h, cells were fixed with 10% trichloroacetic acid (TCA) to represent cell population at the time of compound addition (T 0 ). After additional incubation of DMSO or test compound for 48 h, cells were fixed with 10% TCA, and SRB at 0.4% (w/v) in 1% acetic acid was added to stain cells. Unbound SRB was washed out by 1% acetic acid, and SRB bound cells were solubilized with 10 mM Trizma base. The absorbance was read at a wavelength of 515 nm. Using the absorbance parameters time zero (T 0 ), control growth (C), and cell growth in the presence of the compound (T x ), the percentage growth was calculated at each of the compound concentrations levels. Growth inhibition of 50% (GI 50 ) was calculated from [(T i − T z )/(C − T z )] × 100 = 50, which was the compound concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control cells during the compound incubation.
Western Blot Analysis. 20 PC-3 and A549 cells were treated with vehicle (0.1% DMSO) and a test compound at 1, 2.5, 5, 10, and 20 μM in RPMI 1640 supplemented with 10% FBS for 48 h. The cells were collected and sonicated. Protein concentrations in the resultant lysates were determined by a Bradford protein assay kit (Bio-Rad, Hercules, CA). The protein lysates, containing the same amount of proteins, were subjected to 10% SDS−polyacrylamide gel (10%) electrophoresis. The proteins on the gel were then transferred onto an Immobilon nitrocellulose membrane (Millipore, Bellerica, MA) in a semidry transfer cell. The transblotted membrane was washed twice with Tris-buffered saline containing 0.1% Tween 20 (TBST). After being blocked with TBST containing 5% nonfat milk for 40 min, the membrane was incubated with a primary antibody specific to acetyl-H3 (antibody obtained from Upstate Biotechnology, Inc., Lake Placid, NY), H3 (Upstate Biotechnology), acetyl α-tubulin (Sigma-Aldrich, St. Louis, MO), or α-tubulin (Sigma-Aldrich, St. Louis, MO) (1:3000 dilution) in TBST/1% nonfat milk at 4°C overnight. The membrane was washed three times with TBST for a total of 15 min and then incubated with a goat anti-rabbit or anti-mouse IgG antibody conjugated with horseradish (diluted 1:3000) for 1 h at room temperature. After the samples were washed at least three times with TBST, the signals were developed using the enhanced chemiluminescence system (Pierce). Quantitative analysis of Western blot was done with ImageQuant (Molecular Dynamics, U.S.)
Solubility Determination in Water and Ethanol. Solubility was determinations by the shake-flask method. Briefly, 1 mg of a test compound was added into water or ethanol (1 mL). The mixture was sonicated for 10 min and then shaken for 24 h at room temperature. After centrifugation, an aliquot of the clear supernatant was transferred into vials and the target compound present in the sample was determined by reversed phase HPLC and UV detection at 328 nm.
Pharmacokinetic Evaluation. The in vivo pharmacokinetic study was approved by Institutional Animal Care and Use Committee of National Health Research Institutes. A 1 and 5-mg/mL doing solution was preparing by dissolving appropriate amount compound in a mixture of PEG400/DMSO (80:20,v/v) for intravenous administration and 1% carboxylmethyl cellulose, 0.5% Tween 80 for oral dosing, respectively. Male Sprague−Dawley rats, weighing 250−350 g each (8−10 weeks old), were obtained from BioLASCO, Ilan, Taiwan. Tested compound was separately administered to group of three male rats intravenously (2 mg/kg dose) by a bolus injection to the jugular vein or periorally (20 mg/kg dose). The volume of dosing solution administered was adjusted according to the body weight recorded before dose administration. At 0 (prior to dosing), 2, 5 (IV only), 15, and 30 min and at 1, 2, 4, 6, 8, and 24 h after dosing, a blood sample (∼150 μL) was collected from each animal via the jugular-vein cannula and stored in ice (0−4°C). Plasma was separated from the blood by centrifugation (14,000 × g for 15 min at 4°C) and stored in a freezer (−80°C). All samples were analyzed for the test compound by LC-MS/MS (ABI4000). Data were acquired via multiple reactions monitoring. Plasma concentration data were analyzed with standard noncompartmental method.
Antitumor Activity in Vivo. 21 Female nude mice (NTUH Animal Facility) were 8 weeks old. The animals were fed ad libitum water (reverse osmosis, 1 ppm Cl) and PicoLab rodent diet 20 modified and irradiated LabDiet consisting of 20.0% crude protein, 9.9% crude fat, and 4.7% crude fiber. The mice were housed at National Taiwan University Laboratory Animal Center, NTUMC, on a 12 h light cycle at 21−23°C and 60−85% humidity. Nude mice were maintained in accordance with the Institutional Animal Care and Use Committee procedures and guidelines. Mice were sorted into four groups of seven mice. All doses were administered at a volume of 10 mL/kg (0.2 mL/ 20 g mouse), scaled to the body weight of each animal. Control group 1 mice received vehicle daily po to the end point. Group 2 received reference 1 daily at 200 mg/kg po to the end point. Groups 3 and 4 received compound 8 daily at 200 and 100 mg/kg po, respectively, to the end schedule.
The human A549 lung adenocarcinoma cells used for implantation were harvested during log phase growth and resuspended in phosphate-buffered saline at 5 × 10 7 cells/mL. Each mouse was injected sc in the right flank with 1 × 10 7 cells (0.2 mL cell suspension). Tumor size, in mm 3 , was calculated from the following: tumor volume = w 2 l /2, where w is the width and l is the length in mm of the tumor. Tumor weight can be estimated with the assumption that 1 mg is equivalent to 1 mm 3 of tumor volume. Mice were sorted into four groups of seven mice. Each animal was euthanized when the tumors reached the predetermined end point size of 1000 mm 3 . The time to end point (TTE) for each mouse was calculated by the following equation: TTE = (log 10 (end point volume) − b)/m, where TTE is expressed in days, end point volume is in mm 3 , b is the intercept, and m is the slope of the line obtained by linear regression of a log-transformed tumor growth data set. The data set is comprised of the first observation that exceeded the study end point volume and the three consecutive observations that immediately preceded the attainment of the end point volume. The calculated TTE is usually less than the day on which an animal is euthanized for tumor size. Treatment efficacy was determined from tumor growth delay (TGD), which is defined as the increase in the median TTE for a treatment group compared to the control group, TGD = T − C, expressed in days, or as a percentage of the median TTE of the control group, % TGD = (T − C)/C × 100, where T is the median TTE for a treatment group, C is the median TTE for control group 1. Animals were weighed daily for the first 5 days, then twice weekly until the completion of the study. In addition, we also determined tumor growth inhibition (TGI), whose antitumor effects are expressed as % T/C (treated versus control), dividing the tumor volumes from treatment groups by those of the control groups and multiplied by 100. The mice were examined frequently for overt signs of any adverse, drug-related side effects.
Statistical and Graphical Analyses. The log rank test was used to determine the statistical significance of the difference between the TTE values of two groups. Statistical and graphical analyses were performed with Prism 3.03 (GraphPad) for Windows. The two-tailed statistical analyses were conducted at P = 0.05. Kaplan−Meier plots show the percentage of animals remaining in the study versus time. The Kaplan−Meier plots use the same data set as the log rank test.
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